TC Biopharm Stock (NASDAQ:TCBP)
Previous Close
$0.50
52W Range
$0.08 - $523.20
50D Avg
$3.18
200D Avg
$48.27
Market Cap
$256.50K
Avg Vol (3M)
$377.72K
Beta
0.01
Div Yield
-
TCBP Company Profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
TCBP Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RNAZ | TransCode Therapeutics, Inc. |
| BDRX | Biodexa Pharmaceuticals Plc |
| ICU | SeaStar Medical Holding Corporation |
| ZVSA | ZyVersa Therapeutics, Inc. |
| PHIO | Phio Pharmaceuticals Corp. |
| ALLR | Allarity Therapeutics, Inc. |
| VRAX | Virax Biolabs Group Limited |
| IMMX | Immix Biopharma, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| REVB | Revelation Biosciences, Inc. |
| SONN | Sonnet BioTherapeutics Holdings, Inc. |
| UNCY | Unicycive Therapeutics, Inc. |
| ZURA | Zura Bio Limited |
| PALI | Palisade Bio, Inc. |